About Us

siRNAgen simplifies siRNA therapies using modular chemistry and self assembly to enable delivery to target tissues, including the brain.  siRNAgen is a spin out from Bioneer, Korea’s first biotech and one of world’s leading oligo manufacturers. The lead asset, SRN-001, is expected to begin Phase 1 in Korea in 2023. 

Team

hanohpark.png

Han Oh Park, Founder

  • Grey LinkedIn Icon

Founder & CEO of Bioneer, Adjunct Prof. @ KAIST, member of K. National Academy of Engineering

junepark.png

June Park, CEO

  • Grey LinkedIn Icon

Chemical engineer & healthcare consultant turned supramolecular chemist, Gates Cambridge Scholar

rogerfrechette.png

Roger Frechette, CBO

  • Grey LinkedIn Icon

20+ years experience in the Business of Biotech and R&D operations